News | March 09, 2024
Jagsonpal Pharmaceuticals launches QueeZy-ER
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
The product combines proven efficacy of Doxylamine succinate 20 mg and Pyridoxine hydrochloride 20 mg in an Extended Release formulation
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
The 200 bedded hospital owned & operated by Alexis
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Automated parallel capillary electrophoresis system simplifies protein analysis
Innovent will supply sintilimab for the collaborated clinical trial
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
